The 3rd CRISPR-Based Therapy Analytical Development Summit returns to Boston this September as the only industry-led meeting dedicated exclusively to analytical development for CRISPR-based therapeutics. As the race to the clinic accelerates, developers must deliver robust, regulatory-ready analytical packages to secure IND approval and demonstrate safety, efficacy, and product integrity to both regulators and investors.